vs

Side-by-side financial comparison of FLYEXCLUSIVE INC. (FLYX) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $92.1M, roughly 1.6× FLYEXCLUSIVE INC.). FLYEXCLUSIVE INC. runs the higher net margin — -4.6% vs -5.5%, a 0.9% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 19.8%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $-11.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 21.9%).

FLYEXCLUSIVE INC. is a U.S.-headquartered private aviation services provider that offers private jet charter, aircraft management, maintenance repair, and fractional ownership programs. It primarily serves high-net-worth individuals, corporate clients, and government entities across North America, delivering personalized on-demand air travel solutions prioritizing safety and convenience.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

FLYX vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.6× larger
TARS
$151.7M
$92.1M
FLYX
Growing faster (revenue YoY)
TARS
TARS
+108.6% gap
TARS
128.4%
19.8%
FLYX
Higher net margin
FLYX
FLYX
0.9% more per $
FLYX
-4.6%
-5.5%
TARS
More free cash flow
TARS
TARS
$24.0M more FCF
TARS
$13.0M
$-11.0M
FLYX
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
21.9%
FLYX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
FLYX
FLYX
TARS
TARS
Revenue
$92.1M
$151.7M
Net Profit
$-4.3M
$-8.4M
Gross Margin
13.7%
Operating Margin
-12.3%
-5.3%
Net Margin
-4.6%
-5.5%
Revenue YoY
19.8%
128.4%
Net Profit YoY
32.0%
63.8%
EPS (diluted)
$-0.25
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FLYX
FLYX
TARS
TARS
Q4 25
$151.7M
Q3 25
$92.1M
$118.7M
Q2 25
$91.3M
$102.7M
Q1 25
$88.1M
$78.3M
Q4 24
$66.4M
Q3 24
$76.9M
$48.1M
Q2 24
$79.0M
$40.8M
Q1 24
$80.0M
$27.6M
Net Profit
FLYX
FLYX
TARS
TARS
Q4 25
$-8.4M
Q3 25
$-4.3M
$-12.6M
Q2 25
$-4.8M
$-20.3M
Q1 25
$-5.4M
$-25.1M
Q4 24
$-23.1M
Q3 24
$-6.3M
$-23.4M
Q2 24
$-5.2M
$-33.3M
Q1 24
$-5.8M
$-35.7M
Gross Margin
FLYX
FLYX
TARS
TARS
Q4 25
Q3 25
13.7%
Q2 25
15.0%
Q1 25
12.8%
Q4 24
Q3 24
11.3%
Q2 24
7.9%
Q1 24
7.2%
Operating Margin
FLYX
FLYX
TARS
TARS
Q4 25
-5.3%
Q3 25
-12.3%
-12.2%
Q2 25
-13.5%
-21.6%
Q1 25
-16.7%
-33.5%
Q4 24
-36.8%
Q3 24
-27.2%
-52.3%
Q2 24
-27.6%
-81.6%
Q1 24
-34.3%
-136.5%
Net Margin
FLYX
FLYX
TARS
TARS
Q4 25
-5.5%
Q3 25
-4.6%
-10.6%
Q2 25
-5.2%
-19.8%
Q1 25
-6.2%
-32.1%
Q4 24
-34.8%
Q3 24
-8.2%
-48.7%
Q2 24
-6.5%
-81.6%
Q1 24
-7.3%
-129.4%
EPS (diluted)
FLYX
FLYX
TARS
TARS
Q4 25
$-0.17
Q3 25
$-0.25
$-0.30
Q2 25
$-0.26
$-0.48
Q1 25
$-0.30
$-0.64
Q4 24
$-0.57
Q3 24
$-0.32
$-0.61
Q2 24
$-0.32
$-0.88
Q1 24
$-0.35
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FLYX
FLYX
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$18.7M
$417.3M
Total DebtLower is stronger
$123.9M
$72.4M
Stockholders' EquityBook value
$-434.2M
$343.4M
Total Assets
$448.1M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FLYX
FLYX
TARS
TARS
Q4 25
$417.3M
Q3 25
$18.7M
$401.8M
Q2 25
$15.8M
$381.1M
Q1 25
$14.7M
$407.9M
Q4 24
$291.4M
Q3 24
$18.7M
$317.0M
Q2 24
$9.3M
$323.6M
Q1 24
$5.3M
$298.5M
Total Debt
FLYX
FLYX
TARS
TARS
Q4 25
$72.4M
Q3 25
$123.9M
$72.3M
Q2 25
$111.6M
$72.1M
Q1 25
$121.6M
$72.0M
Q4 24
$71.8M
Q3 24
$197.9M
$71.7M
Q2 24
$206.3M
$71.6M
Q1 24
$209.4M
$29.9M
Stockholders' Equity
FLYX
FLYX
TARS
TARS
Q4 25
$343.4M
Q3 25
$-434.2M
$335.1M
Q2 25
$-261.4M
$332.6M
Q1 25
$-281.5M
$342.5M
Q4 24
$224.5M
Q3 24
$-192.0M
$237.5M
Q2 24
$-149.7M
$252.2M
Q1 24
$-149.5M
$275.2M
Total Assets
FLYX
FLYX
TARS
TARS
Q4 25
$562.2M
Q3 25
$448.1M
$534.6M
Q2 25
$443.4M
$495.0M
Q1 25
$466.8M
$500.8M
Q4 24
$377.0M
Q3 24
$487.1M
$376.3M
Q2 24
$494.7M
$376.8M
Q1 24
$524.1M
$349.3M
Debt / Equity
FLYX
FLYX
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FLYX
FLYX
TARS
TARS
Operating Cash FlowLast quarter
$-209.0K
$19.3M
Free Cash FlowOCF − Capex
$-11.0M
$13.0M
FCF MarginFCF / Revenue
-12.0%
8.6%
Capex IntensityCapex / Revenue
11.7%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-51.0M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FLYX
FLYX
TARS
TARS
Q4 25
$19.3M
Q3 25
$-209.0K
$18.3M
Q2 25
$363.0K
$-29.4M
Q1 25
$-10.5M
$-20.7M
Q4 24
$-22.2M
Q3 24
$-12.3M
$-8.7M
Q2 24
$-16.2M
$-14.4M
Q1 24
$-26.0M
$-37.8M
Free Cash Flow
FLYX
FLYX
TARS
TARS
Q4 25
$13.0M
Q3 25
$-11.0M
$16.3M
Q2 25
$353.0K
$-30.4M
Q1 25
$-14.6M
$-21.2M
Q4 24
$-22.3M
Q3 24
$-25.7M
$-8.9M
Q2 24
$-26.6M
$-15.4M
Q1 24
$-64.5M
$-38.0M
FCF Margin
FLYX
FLYX
TARS
TARS
Q4 25
8.6%
Q3 25
-12.0%
13.8%
Q2 25
0.4%
-29.6%
Q1 25
-16.5%
-27.1%
Q4 24
-33.5%
Q3 24
-33.5%
-18.6%
Q2 24
-33.7%
-37.8%
Q1 24
-80.6%
-137.5%
Capex Intensity
FLYX
FLYX
TARS
TARS
Q4 25
4.2%
Q3 25
11.7%
1.6%
Q2 25
0.0%
1.0%
Q1 25
4.7%
0.8%
Q4 24
0.1%
Q3 24
17.5%
0.6%
Q2 24
13.2%
2.5%
Q1 24
48.2%
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons